U.S. markets open in 7 hours 7 minutes
  • S&P Futures

    3,611.75
    +10.25 (+0.28%)
     
  • Dow Futures

    28,926.00
    +125.00 (+0.43%)
     
  • Nasdaq Futures

    11,035.00
    -0.50 (-0.00%)
     
  • Russell 2000 Futures

    1,679.40
    +9.60 (+0.57%)
     
  • Crude Oil

    81.89
    +2.40 (+3.02%)
     
  • Gold

    1,675.90
    +3.90 (+0.23%)
     
  • Silver

    19.48
    +0.44 (+2.32%)
     
  • EUR/USD

    0.9823
    +0.0022 (+0.23%)
     
  • 10-Yr Bond

    3.8040
    0.0000 (0.00%)
     
  • Vix

    31.62
    -0.22 (-0.69%)
     
  • GBP/USD

    1.1238
    +0.0072 (+0.64%)
     
  • USD/JPY

    144.8740
    +0.1450 (+0.10%)
     
  • BTC-USD

    19,230.96
    -112.98 (-0.58%)
     
  • CMC Crypto 200

    436.66
    -6.76 (-1.53%)
     
  • FTSE 100

    6,893.81
    +12.22 (+0.18%)
     
  • Nikkei 225

    26,215.79
    +278.58 (+1.07%)
     

DBV Technologies to Present at Upcoming Investor Conferences

·2 min read
DBV Technologies S.A.
DBV Technologies S.A.

Montrouge, France, September 2, 2022

DBV Technologies to Present at Upcoming Investor Conferences

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that Daniel Tassé, Chief Executive Officer, DBV Technologies, will participate in upcoming investor conferences in September.

Wells Fargo Healthcare Conference
September 7 – 9, 2022 | In-Person Conference | Boston, MA
Daniel Tassé will be on-site in Boston on Thursday, September 8, 2022 to participate in a fireside chat at 4:20 p.m. ET.

H.C. Wainwright 24rd Annual Global Investment Conference
September 12 – 14, 2022 | Hybrid In-Person and Virtual Conference | New York, NY
Daniel Tassé will be on-site in New York on Monday, September 12, 2022 for a company presentation at 11:00 a.m. ET.

A webcast of each engagement, the fireside chat and company presentation, will be available on the Investors & Media section of the Company’s website: https://www.dbv-technologies.com/investor-relations/.

A replay of both engagements will also be available on DBV Technologies’ website after the events conclude.

About DBV Technologies
DBV Technologies is developing Viaskin™, an investigational proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT™, DBV’s method of delivering biologically active compounds to the immune system through intact skin. With this new class of non-invasive product candidates, the Company is dedicated to safely transforming the care of food allergic patients. DBV’s food allergies programs include ongoing clinical trials of Viaskin Peanut. DBV Technologies has global headquarters in Montrouge, France, and North American operations in Basking Ridge, NJ. The Company’s ordinary shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345), and the Company’s ADSs (each representing one-half of one ordinary share) are traded on the Nasdaq Global Select Market (Ticker: DBVT).

Investor Contact
Anne Pollak
DBV Technologies
+1 857-529-2363
anne.pollak@dbv-technologies.com

Media Contact
Angela Marcucci
DBV Technologies
+1 646-842-2393

angela.marcucci@dbv-technologies.com

Attachment